Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Explore linked clinical trials.14 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo | Skin and Connective Tissue Diseases, hypopigmentation of the skin, skin disorder, skin pigmentation disorder, vitiligo | Not yet recruiting | Phase 1 / Phase 2 | 2026-06-15 | NCT07647237 | |
| A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China. | Healthy Adult Participants; Multiple Dose | Not yet recruiting | Phase 1 | 2026-06-15 | NCT07647224 | |
| GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-05-27 | NCT06566547 | |
| A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-03-25 | NCT07452198 | |
| A Study of GR1803 in Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 1 / Phase 2 | 2026-03-10 | NCT07348055 | |
| A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | Active, not recruiting | Phase 3 | 2026-03-03 | NCT06516302 | |
| A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult | Health Adult Subjects | Recruiting | Phase 1 | 2025-09-30 | NCT07199270 | |
| A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis. | Hypersensitivity, Immediate, Respiratory Hypersensitivity, Rhinitis, Allergic, immune system disorder, nasal disorder, otorhinolaryngologic disease, respiratory system disorder, rhinitis, seasonal allergic rhinitis | Not yet recruiting | Phase 3 | 2025-09-30 | NCT07199257 | |
| A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers. | Healthy Subjects; Single Ascending Dose | Not yet recruiting | Phase 1 | 2025-09-24 | NCT07190716 | |
| A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis | Hypersensitivity, Immediate, Respiratory Hypersensitivity, Rhinitis, Allergic, immune system disorder, nasal disorder, otorhinolaryngologic disease, respiratory system disorder, rhinitis, seasonal allergic rhinitis | Recruiting | Phase 3 | 2025-09-04 | NCT07154342 | |
| A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 1 / Phase 2 | 2025-07-29 | NCT07090954 | |
| GR1803 Injection in Patients With RRMM | Multiple Myleoma | Recruiting | Phase 2 | 2025-04-30 | NCT06952075 | |
| A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR). | Hypersensitivity, Immediate, Respiratory Hypersensitivity, Rhinitis, Allergic, immune system disorder, nasal disorder, otorhinolaryngologic disease, respiratory system disorder, rhinitis | Active, not recruiting | Phase 2 | 2025-04-25 | NCT06315426 | |
| Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Active, not recruiting | Phase 1 / Phase 2 | 2024-09-25 | NCT06015230 |